HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 2372041203v1 237/2/718    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McStay, M. K. G. Articles by Buscombe, J. R. Search for Related Content PubMed PubMed Citation Articles by McStay, M. K. G. Articles by Buscombe, J. R.

Large-Volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial ⁹⁰Y-DOTA-Lanreotide as Effective Palliative Therapy¹

¹ From the Department of Radiology, Royal Free Hospital, Pond St, London NW3 2QG, England. From the 2003 RSNA Annual Meeting. Received July 9, 2004; revision requested September 14; revision received October 27; accepted December 14. Address correspondence to M.E.C.

PURPOSE: To prospectively evaluate the safety and effectiveness of hepatic intraarterial injection of yttrium 90 (⁹⁰Y) tetraazacyclododecane tetraacetic acid (DOTA) lanreotide as a treatment for patients with progressive large-volume somatostatin receptor–positive liver metastases from neuroendocrine tumors.

MATERIALS AND METHODS: The study was local ethics committee approved, and all patients gave informed consent. Twenty-three patients (13 men, 10 women; age range, 21–69 years; median age, 57 years) with histologically proved large-volume liver metastases from neuroendocrine cancers were treated. All patients had radiologic evidence of liver disease progression and high uptake of indium 111 (¹¹¹In) pentetreotide at scintigraphy. Selective hepatic intraarterial injection of ⁹⁰Y-DOTA-lanreotide (total of 36 treatments; median activity per dose, 1 GBq) was administered with or without embolization. Treatment cycles were performed in 8-week intervals. Clinical, biologic, and radiologic tumor responses were assessed 8–12 weeks after each treatment cycle. Objective tumor response was classified according to World Health Organization response criteria as complete regression, partial response, stable disease, or disease progression. Kaplan-Meier survival curves were used to calculate 1-year survivals.

RESULTS: Partial response to treatment was achieved in three (16%) of 19 patients, and stable disease was achieved in 12 (63%). Four (21%) of 19 patients had continued disease progression. Clinical improvement was reported by 14 (61%) of the 23 patients, and a reduction in biologic marker levels was observed in nine (60%) of 15 patients. Reversible hematologic toxicity (National Cancer Institute common toxicity criteria grade > 2) occurred in three patients. The 1-year survival rate was 63% (median survival time, 15 months).

CONCLUSION: Hepatic intraarterial injection of ⁹⁰Y-DOTA-lanreotide is a safe and effective palliative treatment for patients with progressive large-volume somatostatin receptor–positive liver metastases from neuroendocrine tumors.

© RSNA, 2005

This article has been cited by other articles:

				M. J. Steward, V. S. Warbey, A. Malhotra, M. E. Caplin, J. R. Buscombe, and D. Yu Neuroendocrine Tumors: Role of Interventional Radiology in Therapy RadioGraphics, July 1, 2008; 28(4): 1131 - 1145. [Abstract] [Full Text] [PDF]